New Delhi: Assessment of the real-world data about Sputnik V has found Russia’s Covid-19 vaccine demonstrating an efficacy level of 80 per cent post 6-8 months of administering the second dose, the Russian Direct Investment Fund (RDIF) announced on Wednesday.
The data has been collected by the Ministry of Health of the Republic of San Marino, the RDIF said in a statement.
According to RDIF, the data is based on the number of Covid infections in San Marino in November, 2021.
“Efficacy was calculated based on data obtained from over 18,600 individuals fully vaccinated with Sputnik V not less than five months before November,” it said.
According to RDIF, the hospitalisation rate post-vaccination of Sputnik V was reduced to less than one per 1,000 of the population during mass vaccination in San Marino.
“This rate is more than two times lower than that of any other vaccine used in the country,” it stated.
Over 70 per cent of the adult population of San Marino have been vaccinated with Sputnik V, the RDIF added.
RDIF, the sovereign wealth fund of the country, also claimed that the efficacy of Sputnik V post 6-8 months of administering the second dose is much higher than the officially published efficacy of mRNA vaccines.
“Sputnik team believes that adenoviral vaccines provide for longer efficacy than mRNA vaccines due to longer antibody and T-cell response,” it said.
An article published in EClinical Medicine, an open-access clinical journal published by The Lancet in July, found the Russian jab having a high safety profile, particularly in the population above 60 years of age.
“Sputnik V shows high tolerability profile in ≥60 age group with nearly all reported adverse events following immunisation being mild or moderate and lasting less than two days,” the RDIF said.